Regeneron pharmaceuticals, inc. class action notice: robbins llp reminds stockholders of the lead plaintiff deadline in the regn class action

San diego, ca / accesswire / january 15, 2025 / robbins llp reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired regeneron pharmaceuticals, inc. (nasdaq:regn) securities between november 2, 2023 and october 30, 2024. regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
REGN Ratings Summary
REGN Quant Ranking